PGE2

Khondrion announces grant of patents in the US and Europe for its lead candidate sonlicromanol, covering the anti-inflammatory effect on mPGES-1

Retrieved on: 
Wednesday, November 1, 2023
Research, Patent, Inflammation, Prostate cancer, CPEO, Sonlicromanol, European Patent Office, MIDD, Reactive oxygen species, PGE2, MELAS, European Patent Convention, Patient, Mutation, Pharmaceutical industry

Sonlicromanol works in three distinct ways by modulating oxidative and reductive distress, along with anti-inflammatory properties.

Key Points: 
  • Sonlicromanol works in three distinct ways by modulating oxidative and reductive distress, along with anti-inflammatory properties.
  • The compound is currently under investigation for its effectiveness in treating adult patients diagnosed with primary mitochondrial disease due to the m.3243A>G mutation in their mitochondrial DNA.
  • This mutation is linked to various conditions such as classical MELAS and MIDD syndromes, CPEO, and mixed phenotypes.
  • These findings suggest a wider range of potential applications for sonlicromanol beyond its initial focus on primary mitochondrial diseases.

Khondrion announces grant of patents in the US and Europe for its lead candidate sonlicromanol, covering the anti-inflammatory effect on mPGES-1

Retrieved on: 
Wednesday, November 1, 2023
Research, Patent, Inflammation, Prostate cancer, CPEO, Sonlicromanol, European Patent Office, MIDD, Reactive oxygen species, PGE2, MELAS, European Patent Convention, Patient, Mutation, Pharmaceutical industry

Sonlicromanol works in three distinct ways by modulating oxidative and reductive distress, along with anti-inflammatory properties.

Key Points: 
  • Sonlicromanol works in three distinct ways by modulating oxidative and reductive distress, along with anti-inflammatory properties.
  • The compound is currently under investigation for its effectiveness in treating adult patients diagnosed with primary mitochondrial disease due to the m.3243A>G mutation in their mitochondrial DNA.
  • This mutation is linked to various conditions such as classical MELAS and MIDD syndromes, CPEO, and mixed phenotypes.
  • These findings suggest a wider range of potential applications for sonlicromanol beyond its initial focus on primary mitochondrial diseases.

Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732

Retrieved on: 
Thursday, August 10, 2023
DNA, Partnership, University, PD, Cancer research, Health care, MSS, University of Cambridge, Clinical trial, Cancer, Pharmacokinetics, Cancer Research UK, Head, Innovation, Toxicity, Immunotherapy, Neck, ECMC, PGE2, Neoplasm, GPCR, Cambridge University Hospitals NHS Foundation Trust, Patient, Colorectal cancer, Immune system, Drug development, CDD, EP4, Phase, Therapy, Environment, Tumor microenvironment, MHRA, Pharmaceutical industry, Vaccine

HTL0039732 works by blocking signalling through a specific type of prostaglandin receptor, the prostaglandin E2 (PGE2)-type prostanoid receptor 4 (EP4).

Key Points: 
  • HTL0039732 works by blocking signalling through a specific type of prostaglandin receptor, the prostaglandin E2 (PGE2)-type prostanoid receptor 4 (EP4).
  • In cancer, PGE2 acts in the tumor microenvironment to trigger cancer cells to evade the immune system.
  • Phase IIa of the trial will expand the optimal combination dose in up to four cohorts in specified cancer indications.
  • Sosei Heptares holds a license to the results generated under the trial to continue the clinical development and commercialization of HTL0039732.

Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together

Retrieved on: 
Wednesday, July 19, 2023
Biology, EP1, Cancer, American Association for Cancer Research, EP4, PGE2, Therapy, EP2, EP3, HCC, Pharmaceutical industry, Tempest

BRISBANE, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, announced today that in vivo and in vitro data on the unique mechanism of TPST-1495, the company’s novel dual receptor inhibitor of prostaglandin E2 (PGE2) signaling, were published in Cancer Research Communications, a journal of the American Association for Cancer Research.

Key Points: 
  • BRISBANE, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, announced today that in vivo and in vitro data on the unique mechanism of TPST-1495, the company’s novel dual receptor inhibitor of prostaglandin E2 (PGE2) signaling, were published in Cancer Research Communications, a journal of the American Association for Cancer Research.
  • “While the biology of PGE2 in promoting tumor growth and immune suppression is well established, there are still no approved drugs for cancer that effectively block the prostaglandin pathway,” said Tom Dubensky, Ph.D., president of Tempest.
  • “Our innovation with TPST-1495 shows for the first time the effect of blocking PGE2 signaling through the EP2 and EP4 pro-tumor receptors while maintaining the important anti-tumor signaling of PGE2 through the EP1 and EP3 receptors, which could be an important advance to inhibiting PGE2.
  • Additionally, these results further support what we believe is an innovative and robust pipeline at Tempest that includes TPST-1120, a novel PPAR⍺ antagonist, which has shown early positive data from an ongoing global randomized study in first-line HCC patients.”

Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

Retrieved on: 
Thursday, May 25, 2023
Therapy, CRC, Diarrhea, MSS, DCR, Clinical trial, RECIST, Trae tha Truth, Immunotherapy, Abdominal pain, ASCO, PGE2, Endometrial cancer, American Society of Clinical Oncology, Patient, Nausea, Pembrolizumab, Society, Fatigue, Pharmaceutical industry, Tempest

BRISBANE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- May 25, 2023 – Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, announced today that Phase 1 clinical trial data for TPST-1495, the company’s novel dual receptor inhibitor of prostaglandin (PGE2) signaling, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago from June 2-6, 2023.

Key Points: 
  • The first-in-human Phase 1a/1b, multicenter, open-label, dose-escalation trial included patients with metastatic or unresectable solid tumors and treatment-refractory disease with no remaining standard therapy to confer clinical benefit.
  • For the combination with pembrolizumab, the most common TRAEs were nausea (29.2% All Grade and 0% Grade 3+), fatigue (20.8% All Grade and 4.2% Grade 3+) and diarrhea (20.8% All Grade, 0% Grade 3+).
  • TPST-1495 also demonstrated near-linear relationship of exposure-to-dose that was unaffected by combination therapy, and pharmacodynamic activity was observed in assays of both immune activation and PGE2 modulation.
  • “Based on the well-understood biology of PGE2 signaling, we are enrolling patients in a combination therapy cohort focused on endometrial cancer, and we are exploring TPST-1495 monotherapy to treat the high unmet-need inherited cancer syndrome known as familial adenomatous polyposis, or FAP.”

Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study

Retrieved on: 
Thursday, January 5, 2023
Immunosuppression, Cancer, Lead, GPCR, G protein-coupled receptor, Pharmacokinetics, Drug discovery, PGE2, Therapy, Hope, EP4, Trial of the century, Patient, Gq alpha subunit, Safety, Immune system, IO, Institut Jules Bordet, Curie Institute (Paris), Neoplasm, Pharmaceutical industry, Vaccine

In preclinical studies, the asset demonstrated strong anti-tumor effects and synergies with immune checkpoint inhibitors in multiple models.

Key Points: 
  • In preclinical studies, the asset demonstrated strong anti-tumor effects and synergies with immune checkpoint inhibitors in multiple models.
  • The Phase I study, named EPRAD, is a multi-center, open-label study that will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of DT-9081 in adult patients with advanced, recurrent or metastatic solid tumors who have failed standard of care therapies.
  • Dr. Pascal Neuville, CEO of Domain Therapeutics, commented: “The successful initiation of this first-in-human study is a significant milestone for Domain.
  • By blocking the EP4 receptor, I believe that DT-9081 has the potential to address this challenge and offer new hope for patients.

Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with Cancer

Retrieved on: 
Thursday, November 10, 2022
Molecule, SAN, GLOBE, PPAR, Annual general meeting, EP4, Immunotherapy, Gene, Neoplasm, Society for Immunotherapy of Cancer, Therapy, Biomarker, Patient, Gene expression, SITC, Celecoxib, EP2, PGE2, Society, Pharmaceutical industry, Medical imaging, Cancer, Tempest

The biomarker results presented from the TPST-1120 Phase 1 clinical study demonstrate pharmacodynamic changes in circulating blood in patients who received clinical benefit from therapy that are consistent with blocking the activity of PPAR-.

Key Points: 
  • The biomarker results presented from the TPST-1120 Phase 1 clinical study demonstrate pharmacodynamic changes in circulating blood in patients who received clinical benefit from therapy that are consistent with blocking the activity of PPAR-.
  • As we advance the Tempest pipeline, we continue to generate results that validate and differentiate the novel approaches of our product candidates, said Tom Dubensky, Ph.D., president of Tempest.
  • These discoveries may enable us to identify patient populations in future clinical studies that are most likely to benefit from treatment with TPST-1120.
  • Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS/STING pathway.

Domain Therapeutics to progress into clinical trials with its EP4R antagonist DT-9081 in solid tumors

Retrieved on: 
Wednesday, October 19, 2022
News, Neoplasm, Agence nationale de sécurité du médicament et des produits de santé, Patient, Gq alpha subunit, IO, G protein-coupled receptor, Standard of care, Cancer, ANSM, Immune system, Drug discovery, EP4, Pharmaceuticals and Medical Devices Agency, CEO, Immunosuppression, CTA, PGE2, Clinical trial, Pharmaceutical industry

The first-in-human clinical trial is on track to initiate by the end of the year.

Key Points: 
  • The first-in-human clinical trial is on track to initiate by the end of the year.
  • Given the high concentrations of PGE2 exhibited by a range of different solid tumors, Domain Therapeutics has developed an extensive biomarker strategy, enabling optimal selection of tumor types and patient subpopulations and monitoring the target engagement in future clinical trials.
  • Dr. Pascal Neuville, CEO of Domain Therapeutics, commented: Todays news marks a pivotal moment for Domain as we progress our first fully-owned immuno-oncology drug candidate towards the clinic.
  • Dr. Asmaa Boudribila,Medical Director at Domain Therapeutics, commented: DT-9081 is a promising new candidate with the potential to treat a wide range of cancers.

Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 15, 2022
U.S. Securities and Exchange Commission, Hepatocellular carcinoma, PGE2, Securities Act of 1933, Association, ASCO, American Association, Forward-looking statement, GLOBE, Form, DNA repair, Annual general meeting, Clinical trial, Securities Exchange Act of 1934, Society, Security (finance), Research, American Society of Clinical Oncology, Neoplasm, Patient, Pembrolizumab, Therapy, DNA, SAN, HCC, PIPE, Nature, AACR, Â, Goal, Insurance, American Association for Cancer Research, Pharmaceutical industry, Health insurance, Tempest

In the second quarter, we presented promising trial results from TPST-1120, our novel PPAR antagonist, at the ASCO Annual Meeting.

Key Points: 
  • In the second quarter, we presented promising trial results from TPST-1120, our novel PPAR antagonist, at the ASCO Annual Meeting.
  • Tempest ended the second quarter of 2022 with $51.6 million in cash and cash equivalents, compared to $51.8 million at December 31, 2021.
  • Net loss and net loss per share for the second quarter of 2022 were $9.2 million and $0.79, respectively, compared to $7.1 million and $7.63, respectively, for the second quarter of 2021.
  • Research and development expenses for the second quarter of 2022 were $5.7 million compared to $4.2 million for the same period in 2021.

Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials

Retrieved on: 
Friday, July 22, 2022
Novartis, Diagnosis, Atezolizumab, Lipid, Ipilimumab, CTA, Cell, EP4, Clinical trial, AbbVie, Immunotherapy, Hope, Cancer Research UK, Drug development, Neurocrine Biosciences, Infection, Environment, Research, Pembrolizumab, Toxicology, Head, MSS, Cancer, Temozolomide, Takeda, Technology, Heart, Nivolumab, AstraZeneca, Colorectal cancer, Nursing, DNA, Neoplasm, GLOBE, GPCR, Tissue, Twitter, Government, Immune system, Cancer research, Conference, GLP, GSK, Tokyo Stock Exchange, Neck, Survival, Neurology, Ovarian cancer, IMP, Inflammation, Prostate cancer, Gastroenterology, Prostaglandin, Therapy, PGE2, Patient, Brain, Gq alpha subunit, Pharmaceutical industry, Medical imaging, Dietary supplement, Medical device, Fine chemical, Pfizer, Genentech, Facebook

"We are therefore thrilled to be partnering with Sosei Heptares to bring their novel immunotherapy candidate into human trials.

Key Points: 
  • "We are therefore thrilled to be partnering with Sosei Heptares to bring their novel immunotherapy candidate into human trials.
  • Matt Barnes, President of Heptares Therapeutics and Head of UK R&D, commented: We are extremely pleased to collaborate with Cancer Research UK to advance HTL0039732 into Phase I/IIa clinical trials and take a step towards bringing new treatments to cancer patients.
  • Cancer Research UK receives no funding from the UK government for its life-saving research.
  • Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.